How should we evaluate efficacy in modern haemophilia care?

**SAVE THE DATE**

1st February 2017, 14:00–15:30
Paris Marriott Rive Gauche Hotel & Conference Center Paris, France

Meeting Co-chairs:
Martin Schulz (Pfizer)
Claude Négrier (France)

**Agenda**

14:00  **Welcome and introduction**  
Martin Schulz (Pfizer), Claude Négrier (France)

14:05  **How should we evaluate efficacy in haemophilia A: Compliance with treatment?**  
Giovanni Di Minno (Italy)

14:25  **How should we evaluate efficacy in haemophilia: Genotype / phenotype?**  
Andreas Tiede (Germany)

14:45  **How should we evaluate efficacy in haemophilia B: Pharmacokinetics and trough levels?**  
Gerry Dolan (UK), Charles Hay (UK)

15:05  **How do we measure efficacy in an era of gene therapy?**  
Katherine High (USA)

15:25  **Meeting summary**  
Martin Schulz (Pfizer)

15:30  **Meeting close**  

This symposium has been initiated and funded by Pfizer